


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-33 (Canceled).

34. (Currently amended) A compound having a name of trans-1-((1R,3S)-6-chloro-3- phenylindan-1-yl)-3,3-dimethylpiperazine and a the following formula of:



(I);

or a pharmaceutically acceptable salt thereof.

35. (Currently amended) The compound of claim 34, wherein the compound is substantially stereochemically pure.
36. (Previously presented) A pharmaceutical composition comprising the compound of claim 34 and at least one pharmaceutically acceptable carrier, filler or diluent.
37. (Previously presented) The pharmaceutical composition of claim 36, wherein the compound is present in an enantiomeric excess of at least 90%.
38. (Currently amended) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the compound of claim 34, wherein the disease or disorder is selected from the group consisting of schizophrenia, an anxiety disorder, ~~an affective disorder, a~~ depression, ~~a psychotic disorder, a sleep disturbance,~~ migraine, neuroleptic-induced parkinsonism, ~~a disorder exhibiting psychotic symptoms, an abuse~~

~~disorder,~~ Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder.

39. (Currently amended) The method of claim 38, wherein the disease or disorder is schizophrenia-~~or a psychotic disorder~~ Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder ~~[[and]]~~or mania in bipolar disorder.
40. (Previously presented) The method of claim 39, wherein the schizophrenia comprises positive symptoms.
41. (Previously presented) The method of claim 39, wherein the schizophrenia comprises negative symptoms.
42. (Previously presented) The method of claim 39, wherein the schizophrenia comprises depressive symptoms.
43. (Previously presented) The method of claim 38, wherein the subject is treated with at least one other medicament.
44. (Currently amended) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the compound of claim 34, wherein: the disease or disorder is selected from the group consisting of schizophrenia, an anxiety disorder, ~~an affective disorder, a depression, a psychotic disorder, a sleep disturbance, migraine, neuroleptic-induced parkinsonism, a disorder exhibiting psychotic symptoms, an abuse disorder,~~ Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder~~[[,]]~~; and ~~wherein~~ the compound is present in an enantiomeric excess of at least 90%.
- 45-46. (Cancelled)
47. (Currently amended) A pharmaceutical composition comprising the compound of claim ~~[[46]]~~34 and at least one pharmaceutically acceptable carrier, diluent or filler.
- 48-49. (Cancelled)
50. (New) The method of claim 38, wherein the depression is depression in bipolar disorder.
51. (New) The method of claim 44, wherein the depression is depression in bipolar disorder.